# Food and Drug Administration Type: organization Source: GetYourBrief — https://getyourbrief.com/entity/food-and-drug-administration Canonical HTML page: https://getyourbrief.com/entity/food-and-drug-administration ## Timeline - **2026-07-16**: CDC confirms lettuce link and issues warning — The CDC officially identifies Taco Bell lettuce in five states as the outbreak source, warning consumers not to eat shredded iceberg lettuce from those locations. - **2026-07-14**: Taco Bell voluntarily halts lettuce from supplier — Taco Bell temporarily stops using shredded iceberg lettuce from the identified supplier across all affected restaurants ahead of CDC confirmation. - **2026-03-19**: Media Backlash — Health experts and advocacy groups label the bill's scientific claims regarding water pollution as unverified. - **2026-03-18**: Bill Introduction — Rep. Mary Miller introduces the Clean Water For All Life Act in the House. - **2026-03-18**: Press Conference — Miller and Kristan Hawkins (Students for Life) present the bill as an environmental protection measure. - **2026-03-15**: Public Criticism — Major editorials highlight the FDA's 'erratic' behavior as a threat to the broader innovation ecosystem. - **2026-03-15**: Market Impact — Moderna's valuation remains at roughly 10% of its pandemic-era high amid regulatory uncertainty. - **2026-03-15**: Industry Warning — Editorials warn that erratic FDA behavior is a threat to biotech innovation. - **2026-02-03**: Refusal to File — FDA's Vinay Prasad issues a formal refusal to review the flu vaccine application. - **2026-02-03**: Refusal to File — Senior regulator Vinay Prasad refuses to review Moderna's flu vaccine application, citing trial design concerns. - **2026-02-03**: Refusal to File — Senior regulator Vinay Prasad issues a rare letter refusing to review Moderna's flu vaccine application. - **2026-02-03**: Refusal to File — FDA regulator Vinay Prasad refuses to review Moderna's flu vaccine application. - **2026-02-03**: Application Refusal — FDA senior regulator Vinay Prasad issues a formal refusal to review the flu vaccine application. - **2025-12-31**: Grants Rescinded — The administration pulls back hundreds of millions in funding for mRNA-based research projects. - **2025-12-31**: Grants Rescinded — White House rescinds hundreds of millions in mRNA research grants by year-end. ## Recent coverage (12 stories, network-wide) ### Single-Supplier Lettuce Outbreak Hits 5 States in Cross-Border Supply Chain Failure 2026-07-17 15:12:23 · Sector: supply · Sentiment: Negative · Impact: 6/10 · Sources: 7 The Taco Bell cyclospora outbreak traces back to a single Mexican lettuce supplier, Taylor Farms. For supply chain professionals, the event highlights vulnerabilities in fresh produce sourcing, traceability failures, and the cascading impact of a single contaminated source across multiple states. Full story: https://getsupplybrief.com/story/cyclospora-outbreak-supply-chain-risks ### Only 92 Deals: Big Pharma's TrumpRx Offering Covers Under 12% of Its 800+ Drug Stable 2026-07-16 13:49:27 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 12 TrumpRx, the Trump administration's drug discount website, has secured voluntary pricing deals on only 92 brand-name drugs—less than 12% of the 800-plus products from 17 major pharmaceutical companies. High-cost therapies for inflammatory diseases, HIV, and cancer are largely excluded, raising doubts about industry's willingness to compromise on pricing without legislation. Full story: https://getbiobrief.com/story/trumprx-pharma-limited-coverage-92-deals ### FDA Pilot Could Cut Early-Phase Trial Timelines by 12 Months, Boosting Patient Access 2026-06-28 14:13:42 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 6 The FDA is developing a pilot program to accelerate early-stage clinical trials, potentially reducing development timelines by 6 to 12 months, HHS Secretary Kennedy announced. For health systems and patients, this could mean faster access to innovative therapies and a more efficient regulatory pathway. Full story: https://gethealthbrief.com/story/fda-pilot-early-phase-trial-timelines-12-months ### FDA to Cut Trial Timelines 6-12 Months as China Takes 50% of Pharma Deals 2026-06-28 14:12:36 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 6 HHS Secretary Kennedy warns that Chinese companies accounted for nearly half of global pharmaceutical licensing deals in 2025, prompting FDA actions to streamline early-stage trials and potentially reduce drug development times by 6 to 12 months. The shift could reshape US biotech competitiveness and investment returns. Full story: https://getbiobrief.com/story/fda-cut-trial-timelines-china-50-percent-pharma-deals ### GOP Bill Targets Abortion Pill Access via Environmental Water Safety Regulations 2026-03-20 00:33:56 · Sector: bio · Sentiment: Negative · Impact: 6/10 · Sources: 3 House Republicans have introduced the Clean Water For All Life Act, a bill that seeks to restrict abortion pill access by framing fetal remains as environmental pollutants. The legislation would mandate 'catch kits' for patients, ban telehealth prescriptions, and impose severe criminal penalties including five-year prison sentences. Full story: https://getbiobrief.com/story/gop-clean-water-act-abortion-pills ### GOP Bill Proposes 'Catch Kits' and Telehealth Ban for Abortion Pills 2026-03-20 00:33:52 · Sector: health · Sentiment: Negative · Impact: 6/10 · Sources: 3 House Republicans have introduced the Clean Water For All Life Act, a novel regulatory attempt to classify abortion pill remains as environmental pollutants. The bill seeks to mandate 'catch kits' for patients, ban mail-order medication, and impose severe criminal penalties on providers and users. Full story: https://gethealthbrief.com/story/gop-clean-water-act-abortion-telehealth-ban ### GOP's 'Clean Water For All Life Act' Targets Abortion Pills via EPA Regulation 2026-03-20 00:33:18 · Sector: legal · Sentiment: Negative · Impact: 6/10 · Sources: 3 House Republicans have introduced legislation that would criminalize flushing fetal remains, mandating the use of 'catch kits' for medical abortions to prevent alleged water contamination. The bill represents a novel attempt to use environmental protection frameworks to restrict reproductive healthcare access and ban telehealth services. Full story: https://getlegalbrief.com/story/gop-clean-water-act-abortion-pill-regulation ### Regulatory Volatility: FDA’s Moderna Rejection Signals New Risk for Biotech 2026-03-16 00:17:53 · Sector: startups · Sentiment: Negative · Impact: 8/10 · Sources: 2 Moderna faces a significant regulatory setback as the FDA refuses to review its new flu vaccine, citing trial design flaws despite previous guidance. This shift reflects a broader, politically charged environment that threatens to destabilize the venture-backed biotech ecosystem. Full story: https://getstartupbrief.com/story/fda-moderna-regulatory-volatility-biotech-innovation ### FDA Regulatory Shift Threatens Biotech Innovation and Moderna's Recovery 2026-03-16 00:17:19 · Sector: finance · Sentiment: Negative · Impact: 8/10 · Sources: 2 Moderna Inc. faces a critical juncture as the FDA's increasingly erratic regulatory stance and shifting White House sentiment jeopardize the future of mRNA technology. A rare refusal to review the company's flu vaccine data highlights a growing rift between the agency and the industry it oversees, threatening the predictability required for biotech investment. Full story: https://getfinancebrief.com/story/fda-regulatory-shift-moderna-innovation-threat ### FDA Regulatory Volatility and Political Shifts Threaten Moderna’s mRNA Pipeline 2026-03-16 00:16:43 · Sector: bio · Sentiment: Negative · Impact: 8/10 · Sources: 2 Moderna faces a critical setback after the FDA issued a rare refusal to review its flu vaccine application, signaling a shift in the regulatory and political climate for mRNA technology. This development, coupled with rescinded federal grants and a 90% decline in market value from pandemic peaks, highlights growing friction between the biotech industry and federal oversight. Full story: https://getbiobrief.com/story/fda-moderna-mrna-regulatory-threat ### FDA's Regulatory Shift Signals New Era of Uncertainty for mRNA Innovation 2026-03-16 00:16:10 · Sector: health · Sentiment: Negative · Impact: 8/10 · Sources: 2 The FDA's recent refusal to review Moderna's flu vaccine application marks a significant pivot in the regulatory environment for mRNA technology. This shift, characterized by increasing political pressure and unpredictable oversight, threatens to stifle the very innovation that defined the pandemic response. Full story: https://gethealthbrief.com/story/fda-moderna-mrna-regulatory-uncertainty ### FDA Regulatory Shifts and Moderna's Flu Vaccine Setback Threaten Innovation 2026-03-16 00:09:34 · Sector: legal · Sentiment: Negative · Impact: 8/10 · Sources: 2 The FDA's rare 'refusal to file' regarding Moderna's mRNA flu vaccine signals a pivot from pandemic-era collaboration to a more adversarial regulatory environment. This unpredictability, combined with rescinded federal grants and a 90% decline in market value, highlights the growing legal and compliance risks for biotech firms. Full story: https://getlegalbrief.com/story/fda-moderna-regulatory-risk-analysis --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.